Dr Reddy's Labs launches Ephedrine Sulfate Injection in US
Hyderabad: Dr. Reddy's Laboratories Ltd. has recently announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL in the U.S. Market.
The product is a therapeutic equivalent generic version of Akovaz (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA).
Ephedrine sulfate injection is an alpha- and betaadrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Dr. Reddy's Ephedrine Sulfate Injection USP, 50 mg/mL is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap.
Each mL contains 50 mg of ephedrine sulfate USP, equivalent to 38 mg ephedrine base.
The Akovaz brand and generic market had U.S. sales of approximately $67.5 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.
Akovaz is a trademark of EXELA STERILE MEDICINES LLC.
Read also: Dr Reddys, MSN Labs launch of generic Empagliflozin may lead to court battle
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
